Qnexa is a weight loss drug approved by the FDA on July 17, 2012 and will be sold as Qsymia.
UPDATE 7/17/12: Qnexa was approved by the FDA on July 17, 2012. This marks the second weight loss drug approval in 2012; the first weight loss drugs approved since Alli in 1999.
UPDATE 12/30/11: Qnexa Resubmits for FDA Approval with a New Clinical Trial
Qnexa, a prescription weight loss pill created by the pharmaceutical company Vivus Inc., has recently been touted as a promising tool to help those who are desperate to lose weight.
On July 16, 2010, the FDA completed its review of the diet pill, even though it had previously met some of the regulatory body's guidelines to be labeled as an effective weight loss drug. In preliminary clinical trials, individuals who took Qnexa lost between 13 and 15 percent of their body weight. It would have been the first new diet pill in a decade.
Qnexa is a combination of two drugs: the amphetamine phentermine and topiramate, an anti-convulsant drug sold by Johnson & Johnson as Topamax. According to Vivus, phentermine helps suppress appetite, while topiramate makes patients feel more satiated.
Yet it is not without side effects. From birth defects to memory problems, Qnexa is far from a risk-free solution to weight loss. Although Qnexa was originally rejected by the FDA, a third study was conducted in April 2011 on the efficacy of the drug. This study showed that over a two-year period, people taking the drug experienced lower blood pressure and improved lipid levels. These numbers were key in the FDA accepting Qnexa’s second application as a weight loss drug. The drug is set for a five-month trial period and the FDA will announce their decision in April 2012.
- May support weight loss
- Displayed promising results in clinical trials
- Available by prescription only
- Trial studies showed side effects such as memory and concentration difficulties
- May cause birth defects and "low level" psychiatric side effects
- May be misused as a magic pill for weight loss
- Long-term results are unknown
- Does not address root cause of overeating
- If the drug is approved, it will not be available to women of childbearing age
It is not yet known what kind of a diet should be followed while taking Qnexa. The prescription weight loss pill is supposed to suppress appetite, which will help offset the physical urge to eat, but whether it also addresses the emotional side of eating is uncertain.EXERCISE
At this time, there is no information available on whether or not a fitness plan is recommended for people taking Qnexa.CONCLUSION
Qnexa, a prescription weight loss drug created by the company Vivus, Inc., was rejected by the FDA July 16, 2010 because it did not meet its guidelines for efficacy and safety.
While the drug has shown promise in early clinical trials for weight loss, it does so at a price of other side effects. Qnexa's application was approved by the FDA and a decision will be made in April 2012 on if the drug will be released. The side effects are still an issue when it comes to birth defects though because if the drug is accepted, women of childbearing age will not be able to take it.
Prescription weight loss drugs like Qnexa are designed to help those who are overweight and obese reduce their caloric intake, but no such medications have been able to address the real issues of overeating.Common Misspellings
qnecksa, nexa, qenexa, quenexa, qunxa